We determined airway mucosal blood flow (Qaw) and FEV1 before and after inh
aled albuterol in 19 glucocorticosteroid (GS)-naive patients with mild inte
rmittent asthma, and assessed the effects of a 2-wk course of fluticasone p
ropionate (FP; 440 mu g daily) on these parameters. Twelve healthy nonsmoke
rs served as controls. Baseline Qaw was 55.5 +/- 0.7 mu l/min/ml (mean +/-
SE) in the asthmatic subjects and 44.2 +/- 0.7 mu l/min/ml in the controls;
the respective FEV1 values were 2.8 +/- 0.2 L and 3.4 +/- 0.2 L (p < 0.01
for both parameters). Albuterol increased Qaw by 27 +/- 3% in the control s
ubjects (p < 0.01) but had no effect on Qaw in the asthmatic subjects; it i
ncreased FEV1 by 7 +/- 1% and 6 +/- 1% in the two groups, respectively. Qaw
decreased to 49.2 +/- 0.8 mu l/min/ml (p < 0.05 versus baseline), and the
Qaw responsiveness to albuterol was restored (+21 +/- 2%; p < 0.05) in the
asthmatic subjects after FP. Eleven asthmatic subjects stopped using FP at
this time; 2 wk later, their Qaw returned to baseline (55.2 +/- 0.9 mu l/mi
n/ml) and they lost the Qaw responsiveness to albuterol, Mean (+/- SE) FEV1
and FEV1 responsiveness to albuterol were not affected by FP, The GS-sensi
tive increase in Qaw and its hyporesponsiveness to albuterol in asthmatic s
ubjects may be consequences of airway inflammation.